Citation Report
List of articles citing

Predicting drug-drug interactions: an FDA perspective

DOI: 10.1208/s12248-009-9106-3
AAPS Journal, 2009, 11, 300-6.

#	Paper	IF	Citations
201	Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. **2009**, 6, 1766-74		55
200	Transporter-mediated drug-drug interaction in renal and hepatic elimination processes. **2010**, 135, 34-7		
199	Quantitative clinical pharmacology is transforming drug regulation. **2010**, 37, 617-28		19
198	Drug interactions evaluation: an integrated part of risk assessment of therapeutics. **2010**, 243, 134-45		98
197	Therapeutic protein-drug interactions and implications for drug development. **2010**, 87, 497-503		124
196	Combining targeted therapies: practical issues to consider at the bench and bedside. **2010**, 15, 37-50		38
195	In vivo and In vitro Drug Interactions Study of Glimepride with Atorvastatin and Rosuvastatin. **2010**, 2, 196-200		14
194	Current Strategies and Future Trends. **2010**, 353-429		
193	Human Biotransformation. **2010**, 1-77		7
192	The use of herbal preparations as complementary and alternative medicine (CAM) in a sample of patients with cancer in Jordan. **2010**, 16, 208-12		57
191	CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. **2010**, 49, 295-310		87
190	Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis. **2011**, 84, 517-31		133
189	Herbal preparation use by patients suffering from cancer in Palestine. **2011**, 17, 235-40		54
188	Regulatory Considerations in Metabolism- and Transporter-Based Drug Interactions. **2011**, 413-429		
187	Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development. **2011**, 26, 147-68		11
186	Drug transporters of platinum-based anticancer agents and their clinical significance. **2011**, 14, 22-34		154
185	Physiologically-based pharmacokinetics in drug development and regulatory science. **2011**, 51, 45-73		472

184	Principles of Pharmacokinetics: Predicting Human Pharmacokinetics in Drug Discovery. **2011**, 197-228		
183	The neuroprotective agent DP-b99 does not interact with s-warfarin in vivo despite significant CYP2C9 inhibition in vitro. **2011**, 108, 289-92		3
182	Drugs in porphyria: From observation to a modern algorithm-based system for the prediction of porphyrogenicity. **2011**, 132, 158-69		36
181	The use of 13C-erythromycin as an in vivo probe to evaluate CYP3A-mediated drug interactions in rats. **2011**, 100, 3995-4005		6
180	Automated applications of sandwich-cultured hepatocytes in the evaluation of hepatic drug transport. **2011**, 16, 427-35		6
179	Luciferin IPA-based higher throughput human hepatocyte screening assays for CYP3A4 inhibition and induction. **2011**, 16, 903-9		24
178	ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. **2011**, 12, 600-20		123
177	Quinidine as an ABCB1 probe for testing drug interactions at the blood-brain barrier: an in vitro in vivo correlation study. **2011**, 16, 886-94		25
176	Evaluation of organic anion-transporting polypeptide 1B1 and CYP3A4 activities in primary human hepatocytes and HepaRG cells cultured in a dynamic three-dimensional bioreactor system. **2012**, 343, 145-56		17
175	Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor. **2012**, 91, 700-8		34
174	Analytical Method Development and Validation in Accordance to the Regulatory Guidelines. **2012**, 1		
173	The Challenges Involved in Modeling Toxicity Data In Silico: A Review. **2012**, 18, 1266-1291		4
172	Drug-drug interaction through molecular structure similarity analysis. **2012**, 19, 1066-74		121
171	Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors. *Drug Metabolism and Disposition*, **2012**, 40, 2239-49	4	2
170	Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein. *Drug Metabolism and Disposition*, **2012**, 40, 1883-93	4	49
169	The challenges involved in modeling toxicity data in silico: a review. **2012**, 18, 1266-91		67
168	Physiologically based pharmacokinetic models: integration of in silico approaches with micro cell culture analogues. **2012**, 13, 863-80		10
167	INDI: a computational framework for inferring drug interactions and their associated recommendations. **2012**, 8, 592		131

166	Drug Drug Interactions 1: Inhibition. **2012**, 1		
165	Introduction to Drug Metabolism. **2012**, 285-300		3
164	Mechanisms and Genetics of Drug Transport. **2012**, 217-237		
163	In Silico Models of Drug Metabolism and Drug Interactions. **2012**, 1		1
162	Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells. **2012**, 87, 64-9		10
161	Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients. **2012**, 74, 835-41		18
160	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. **2012**, 20, 5388-95		55
159	Intestinal Transporters. **2012**, 430-451		
158	Optimal ADME Properties for Clinical Candidate and Investigational New Drug (IND) Package. **2012**, 15-28		2
157	Physiologically-Based Pharmacokinetic Modeling of Populations. **2012**, 383-399		
156	Overview of Drug Metabolism and Pharmacokinetics with Applications in Drug Discovery and Development in China. **2012**, 109-127		
155	Organotypic liver culture models: meeting current challenges in toxicity testing. **2012**, 42, 501-48		252
154	Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms. **2012**, 52, 617-48		212
153	Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. **2012**, 68, 709-14		16
152	Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach. *AAPS Journal*, **2013**, 15, 1242-52	3.7	34
151	Drug transporters in drug discovery and development. **2013**, 633-674		2
150	In vitro approach to predict post-translational phosphorylation response to mixtures. **2013**, 313, 113-21		9
149	Induction of cytochrome P450 enzymes in primary equine hepatocyte culture. **2013**, 27, 2023-30		9

148	Informatics confronts drug-drug interactions. **2013**, 34, 178-84		101
147	A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6. **2013**, 94, 260-8		62
146	How is a metabolic intermediate formed in the mechanism-based inactivation of cytochrome P450 by using 1,1-dimethylhydrazine: hydrogen abstraction or nitrogen oxidation?. **2013**, 19, 7361-9		30
145	A network inference method for large-scale unsupervised identification of novel drug-drug interactions. **2013**, 9, e1003374		36
144	Text Mining Driven Drug-Drug Interaction Detection. **2013**, 349-355		17
143	P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism. *Drug Metabolism and Disposition*, **2013**, 41, 642-50	4	15
142	Application of a higher throughput approach to derive apparent Michaelis-Menten constants of isoform-selective p450-mediated biotransformation reactions in human hepatocytes. **2014**, 8, 2-11		6
141	Effect of botanical immunomodulators on human CYP3A4 inhibition: implications for concurrent use as adjuvants in cancer therapy. **2014**, 13, 167-75		17
140	Evaluation of drug interaction potential of Labisia pumila (Kacip Fatimah) and its constituents. **2014** , 5, 178		18
139	Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe. **2014**, 5, 261		8
138	A numerical method for analysis of in vitro time-dependent inhibition data. Part 1. Theoretical considerations. *Drug Metabolism and Disposition*, **2014**, 42, 1575-86	4	19
137	Polyamines and membrane transporters. **2014**, 46, 655-60		69
136	Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro. **2014**, 44, 792-803		4
135	In pursuit of the ideal antifungal agent for Candida infections: high-throughput screening of small molecules. **2014**, 19, 1721-1730		40
134	In Vitro Approaches to Study Drug□Drug Interactions. **2014**, 441-484		1
133	MDR1 and OAT1/OAT3 mediate the drug-drug interaction between puerarin and methotrexate. **2014**, 31, 1120-32		23
132	Use of different parameters and equations for calculation of IC□values in efflux assays: potential sources of variability in IC□determination. *AAPS Journal*, **2014**, 16, 172-80	3.7	35
131	A case study of in silico modelling of ciprofloxacin hydrochloride/metallic compound interactions. **2014**, 15, 270-8		6

130	Mining clinical text for signals of adverse drug-drug interactions. **2014**, 21, 353-62		104
129	QSAR analysis of the effects of OATP1B1 transporter by structurally diverse natural products using a particle swarm optimization-combined multiple linear regression approach. **2014**, 130, 84-90		16
128	ADME Profiling. **2015**, 353-377		1
127	Biotransformation of Xenobiotics. **2015**, 172-211		
126	Combining Targeted Therapies. **2015**, 14-26		
125	Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines. **2015**, 67, 1575-84		5
124	In Vitro Evaluation of Reversible and Time-Dependent Inhibitory Effects of Kalanchoe crenata on CYP2C19 and CYP3A4 Activities. **2015**, 9, 48-62		8
123	Hepatocyte-Based Metabolism, Drug□Drug Interaction, and Toxicity Assays in Drug Discovery and Drug Development to Minimize Attrition. **2015**, 1-15		
122	. **2015**,		5
121	Large-scale exploration and analysis of drug combinations. **2015**, 31, 2007-16		79
120	Effects of Ayurvedic Rasayana botanicals on CYP3A4 isoenzyme system. **2015**, 13, 165-72		4
119	Diclofenac- and Pantoprazole-Induced Rhabdomyolysis: A Potential Drug Interaction. **2015**, 2, 10		3
118	Membrane Assays to Characterize Interaction of Drugs with ABCB1. **2015**, 248, 967-77		6
117	In silico methods for predicting drug-drug interactions with cytochrome P-450s, transporters and beyond. **2015**, 86, 46-60		24
116	In Vivo Imaging of Human MDR1 Transcription in the Brain and Spine of MDR1-Luciferase Reporter Mice. *Drug Metabolism and Disposition*, **2015**, 43, 1646-54	4	9
115	Inhibition of P-glycoprotein Gene Expression and Function Enhances Triptolide-induced Hepatotoxicity in Mice. **2015**, 5, 11747		35
114	Pharmacokinetic drug-drug interaction assessment of peptibody trebananib in combination with chemotherapies. **2015**, 76, 243-50		1
113	Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model. *Drug Metabolism and Disposition*, **2015**, 43, 1417-29	4	34

112	Pharmacokinetic interactions between drugs and dietary supplements: herbal supplements. **2015**, 47-68		
111	Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases. **2015**, 58, 897-911		33
110	Inhibition of CYP2B6 by Medicinal Plant Extracts: Implication for Use of Efavirenz and Nevirapine-Based Highly Active Anti-Retroviral Therapy (HAART) in Resource-Limited Settings. **2016**, 21,		25
109	In Vitro Reversible and Time-Dependent CYP450 Inhibition Profiles of Medicinal Herbal Plant Extracts Newbouldia laevis and Cassia abbreviata: Implications for Herb-Drug Interactions. **2016**, 21,		19
108	Generalized enrichment analysis improves the detection of adverse drug events from the biomedical literature. **2016**, 17, 250		9
107	P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate. **2016**, 306, 27-35		38
106	A probabilistic approach for collective similarity-based drug-drug interaction prediction. **2016**, 32, 3175-3182		61
105	The Role of Interaction Model in Simulation of Drug Interactions and QT Prolongation. **2016**, 2, 339-344		10
104	Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions. **2016**, 13, 839-51		22
103	Evaluating the Disposition of a Mixed Aldehyde Oxidase/Cytochrome P450 Substrate in Rats with Attenuated P450 Activity. *Drug Metabolism and Disposition*, **2016**, 44, 1296-303	4	15
102	Complementary and alternative medicine use among cancer patients in Palestine with special reference to safety-related concerns. **2016**, 187, 104-22		30
101	Modulation of CYPs, P-gp, and PXR by Eschscholzia californica (California Poppy) and Its Alkaloids. **2016**, 82, 551-8		8
100	TargetNet: a web service for predicting potential drug-target interaction profiling via multi-target SAR models. **2016**, 30, 413-24		118
99	Introduction to Organ Fabrication. **2016**, 1-30		
98	Tissue Engineering for the Heart. **2016**,		
97	The regulation of human hepatic drug transporter expression by activation of xenobiotic-sensing nuclear receptors. **2016**, 12, 1463-1477		14
96	Modeling Organic Anion-Transporting Polypeptide 1B1 Inhibition to Elucidate Interaction Risks in Early Drug Design. **2016**, 105, 3214-3220		2
95	African Lettuce (Launaea taraxacifolia) Displays Possible Anticancer Effects and Herb-Drug Interaction Potential by CYP1A2, CYP2C9, and CYP2C19 Inhibition. **2016**, 20, 528-37		11

94	Factors that Impact the Developability of Drug Candidates. **2016**, 1-18		2
93	Discovery and Optimization of 1-Phenoxy-2-aminoindanes as Potent, Selective, and Orally Bioavailable Inhibitors of the Na/H Exchanger Type 3 (NHE3). **2016**, 59, 8812-8829		6
92	Leveraging syntactic and semantic graph kernels to extract pharmacokinetic drug drug interactions from biomedical literature. **2016**, 10 Suppl 3, 67		11
91	Assessment of cytochrome P450 inhibition and induction potential of lupeol and betulin in rat liver microsomes. **2016**, 31, 115-22		7
90	Pharmacokinetic herb-drug interactions with traditional Chinese medicine: progress, causes of conflicting results and suggestions for future research. **2016**, 48, 1-26		39
89	Feasibility of Prioritizing Drug-Drug-Event Associations Found in Electronic Health Records. **2016**, 39, 45-57		29
88	Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA. **2016**, 55, 475-83		66
87	Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. **2017**, 47, 77-85		23
86	Preincubation-dependent and long-lasting inhibition of organic anion transporting polypeptide (OATP) and its impact on drug-drug interactions. **2017**, 177, 67-80		41
85	Monitoring drug-serum protein interactions for early ADME prediction through Surface Plasmon Resonance technology. **2017**, 144, 188-194		29
84	Gold nanoparticles based sensor for in vitro analysis of drug-drug interactions using imipramine and isoniazid drugs: A proof of concept approach. **2017**, 252, 1055-1062		8
83	Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies. *Drug Metabolism and Disposition*, **2017**, 45, 260-268	4	16
82	Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling. **2017**, 40, 1356-1379		36
81	Integration of Genome Scale Metabolic Networks and Gene Regulation of Metabolic Enzymes With Physiologically Based Pharmacokinetics. **2017**, 6, 732-746		10
80	MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption. **2017**, 61,		18
79	ChemSAR: an online pipelining platform for molecular SAR modeling. **2017**, 9, 27		29
78	Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in humans. **2017**, 47, 332-345		11
77	Drug-Drug Interactions (DDIs) Detection from On-Line Health Forums: Bi-Submodular Optimization (BSMO). **2017**,		

76	Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. **2018**, 154, 10-17	29
75	Human and mouse artificial chromosome technologies for studies of pharmacokinetics and toxicokinetics. **2018**, 33, 17-30	15
74	Relationships of Changes in Pharmacokinetic Parameters of Substrate Drugs in Drug-Drug Interactions on Metabolizing Enzymes and Transporters. **2018**, 58, 1053-1060	2
73	New insights in the in vitro characterisation and molecular modelling of the P-glycoprotein inhibitory promiscuity. **2018**, 121, 85-94	10
72	Detection of drug-drug interactions through data mining studies using clinical sources, scientific literature and social media. **2018**, 19, 863-877	62
71	Translational High-Dimensional Drug Interaction Discovery and Validation Using Health Record Databases and Pharmacokinetics Models. **2018**, 103, 287-295	14
70	Bush mint (Hyptis suaveolens) and spreading hogweed (Boerhavia diffusa) medicinal plant extracts differentially affect activities of CYP1A2, CYP2D6 and CYP3A4 enzymes. **2018**, 211, 58-69	15
69	Identification of □or (□1)-Hydroxylated Medium-Chain Acylcarnitines as Novel Urinary Biomarkers for CYP3A Activity. **2018**, 103, 879-887	8
68	Pharmacological, Physiochemical, and Drug-Relevant Biological Properties of Short Chain Fatty Acid Hexosamine Analogues Used in Metabolic Glycoengineering. **2018**, 15, 705-720	8
67	GA-ADE: a novel approach based on graph algorithm to improves the detection of adverse drug events. **2018**, 77, 3493-3507	1
66	Predicting adverse drug reactions of combined medication from heterogeneous pharmacologic databases. **2018**, 19, 517	10
65	Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics. **2018**, 14, 1315-1330	7
64	A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide. **2018**, 7, 829-837	2
63	Application of in vitro CYP and transporter assays to predict clinical drug-drug interactions. **2018**, 10, 619-623	8
62	HPLC-high-resolution mass spectrometry with polarity switching for increasing throughput of human in vitro cocktail drug-drug interaction assay. **2018**, 10, 659-671	1
61	A fully automated and validated human plasma LC-MS/MS assay for endogenous OATP biomarkers coproporphyrin-I and coproporphyrin-III. **2018**, 10, 691-701	9
60	Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance. *Drug Metabolism and Disposition*, **2018**, 46, 1285-1303	4 25
59	Drug□Drug Interaction Studies. **2018**, 1-20	

58	Early Drug Development. **2018**, 549-580		
57	Cloning and Transcriptional Activity Analysis of the Porcine Abcb1 Gene Promoter: Transcription Factor Sp1 Regulates the Expression of Porcine Abcb1. **2018**, 9, 373		3
56	Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. **2018**, 19,		42
55	Organic Anion-Transporting Polypeptide Genes Are Not Induced by the Pregnane X Receptor Activator Rifampin: Studies in Hepatocytes In Vitro and in Monkeys In Vivo. *Drug Metabolism and Disposition*, **2019**, 47, 1433-1442	4	9
54	Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF) using an in vivo cocktail approach. **2019**, 245, 112174		19
53	Ultra-High-Precision, Pharmacokinetic Measurements Highlight the Need for and a Route Toward More Highly Personalized Medicine. **2019**, 6, 69		14
52	Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers. **2019**, 34, 247-252		8
51	Transcriptomic profiling identifies novel mechanisms of transcriptional regulation of the cytochrome P450 (Cyp)3a11 gene. **2019**, 9, 6663		7
50	Safe and Appropriate Use of Methadone in Hospice and Palliative Care: Expert Consensus White Paper. **2019**, 57, 635-645.e4		24
49	Simultaneous determination of donepezil, 6-O-desmethyl donepezil and spinosin in beagle dog plasma using liquid chromatography-tandem mass spectrometry and its application to a drug-drug interaction study. **2020**, 178, 112919		3
48	Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R). **2020**, 63, 2292-2307		9
47	Deep learning for drug-drug interaction extraction from the literature: a review. **2020**, 21, 1609-1627		20
46	Adverse pharmacokinetic interactions between illicit substances and clinical drugs. **2020**, 52, 44-65		9
45	Drug Drug Interaction Studies. **2020**, 827-846		
44	Antagonistic interaction between TTA-A2 and paclitaxel for anti-cancer effects by complex formation with T-type calcium channel. **2020**, 1-12		12
43	Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments. **2020**, 151, 102982		15
42	Ser100-Phosphorylated ROR Orchestrates CAR and HNF4 to Form Active Chromatin Complex in Response to Phenobarbital to Regulate Induction of CYP2B6. **2020**, 97, 191-201		3
41	Fundamentals of physiologically based pharmacokinetic modeling. **2020**, 57-80		1

40	Natural Products as Modulators of CES1 Activity. *Drug Metabolism and Disposition*, **2020**, 48, 993-1007	4	5
39	Biological network analysis with deep learning. **2021**, 22, 1515-1530		21
38	Physiologically-based pharmacokinetic modeling after drug inhalation. **2021**, 319-358		1
37	Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator. *Drug Metabolism and Disposition*, **2021**, 49, 389-394	4	1
36	Influence of vitamin D treatment on functional expression of drug disposition pathways in human kidney proximal tubule cells during simulated uremia. **2021**, 51, 657-667		
35	Messenger RNA Expression of Albumin, Transferrin, Transthyretin, Asialoglycoprotein Receptor, Cytochrome P450 Isoform, Uptake Transporter, and Efflux Transporter Genes as a Function of Culture Duration in Prolonged Cultured Cryopreserved Human Hepatocytes as Collagen-Matrigel Sandwich Cultures: Evidence for Redifferentiation upon Prolonged Culturing. *Drug Metabolism and Disposition*, **2021**, 49, 799-807	4	0
34	Drug-Metabolizing Enzymes and Drug Toxicity. **2021**, 79-137		
33	A prospective whole-mixture approach to assess risk of the food and chemical exposome.		4
32	Review of unsupervised pretraining strategies for molecules representation. **2021**, 20, 323-332		6
31	Effect of Water Extract of Mangosteen Pericarp on Donepezil Pharmacokinetics in Mice. **2021**, 26,		1
30	Non-competitive interactions between hydroxychloroquine and azithromycin: Systematic density functional, molecular dynamics, and docking calculations. **2021**, 777, 138745		2
29	Application of Deep Neural Network Models in Drug Discovery Programs. **2021**,		0
28	Scientific Perspectives on Therapeutic Protein Drug Drug Interaction Assessments. 1		1
27	Pharmacokinetics and Bioavailability Enhancement of Natural Products. **2020**, 109-141		2
26	Provenance-Centered Dataset of Drug-Drug Interactions. **2015**, 293-300		7
25	Introduction to Drug-Drug Interactions. **2018**, 1-13		1
24	Piceatannol exhibits potential food-drug interactions through the inhibition of human UDP-glucuronosyltransferase (UGT) in Vitro. **2020**, 67, 104890		3
23	Network neighbors of drug targets contribute to drug side-effect similarity. **2011**, 6, e22187		75

22	Detection of drug-drug interactions by modeling interaction profile fingerprints. **2013**, 8, e58321	61
21	Cytochrome P450 Enzymes, Drug Transporters and their Role in Pharmacokinetic Drug-Drug Interactions of Xenobiotics: A Comprehensive Review. 001-011	3
20	Prediction of Drug-Drug Interactions Related to Inhibition or Induction of Drug-Metabolizing Enzymes. **2019**, 19, 319-336	12
19	Inhibition of major drug metabolizing CYPs by common herbal medicines used by HIV/AIDS patients in Africa-- implications for herb-drug interactions. **2014**, 7, 83-95	32
18	Pharmacokinetic drug interactions in liver disease: An update. **2016**, 22, 1260-78	43
17	Drug-transporter interaction testing in drug discovery and development. **2013**, 2, 35	10
16	Drug Interactions. **2014**, 351-371	
15	Probe Cocktail Studies. **2018**, 259-284	
14	Potential Drug-drug Interactions in Post-CCU of a Teaching Hospital. **2013**, 12, 243-8	8
13	Learning signals of adverse drug-drug interactions from the unstructured text of electronic health records. **2013**, 2013, 83-7	3
12	Mechanisms and genetics of drug transport. **2022**, 213-239	0
11	The Effect of Oral Letermovir Administration on the Pharmacokinetics of a Single Oral Dose of P-Glycoprotein Substrate Digoxin in Healthy Volunteers. **2021**,	0
10	A Review of Approaches for Predicting Drug-Drug Interactions Based on Machine Learning.. **2021**, 12, 814858	1
9	Ceftazidime and cefepime antagonize 5-fluorouracil's effect in colon cancer cells.. **2022**, 22, 125	
8	Approaches to minimize the effects of P-glycoprotein in drug transport: A review.. **2022**,	2
7	Drug–drug interactions and their implications on the pharmacokinetics of the drugs. **2022**, 291-322	
6	A multi-task graph convolutional network modeling of drug-drug interactions and synergistic efficacy. **2021**,	
5	Table_1.docx. **2019**,	

4	A review of bioinformatics tools and web servers in different microarray platforms used in cancer research. *Advances in Protein Chemistry and Structural Biology*, **2022**,	5.3	0
3	Transporters in Regulatory Science: Notable Contributions from Dr. Giacomini in the Past Two Decades. *Drug Metabolism and Disposition*, DMD-MR-2021-000706	4	1
2	Knowledge Mining of Interactions between Drugs from the Extensive Literature with a Novel Graph-Convolutional-Network-Based Method. **2023**, 12, 311		1
1	Development of a Rapid LC-MS/MS Method for Simultaneous Quantification of Donepezil and Tadalafil in Rat Plasma: Its Application in a Pharmacokinetic Interaction Study after Oral Administration in Rats. **2023**, 28, 2352		0